Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Fortress Biotech, Inc. (FBIO)

0.6513   -0.01 (-1.51%) 12-02 16:00
Open: 0.6242 Pre. Close: 0.6613
High: 0.6609 Low: 0.6242
Volume: 101,345 Market Cap: 71(M)

Technical analysis

as of: 2022-12-02 4:22:41 PM
Overall:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 0.91     One year: 1.03
Support: Support1: 0.62    Support2: 0.51
Resistance: Resistance1: 0.78    Resistance2: 0.88
Pivot: 0.76
Moving Average: MA(5): 0.66     MA(20): 0.76
MA(100): 0.91     MA(250): 1.25
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 14.6     %D(3): 13.9
RSI: RSI(14): 32.5
52-week: High: 2.77  Low: 0.62
Average Vol(K): 3-Month: 194 (K)  10-Days: 234 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ FBIO ] has closed above bottom band by 17.2%. Bollinger Bands are 16.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.66 - 0.67 0.67 - 0.67
Low: 0.61 - 0.62 0.62 - 0.62
Close: 0.64 - 0.65 0.65 - 0.66

Company Description

Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; ConVax; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Island, New York.

Headline News

Fri, 02 Dec 2022
Stocks Lower Friday as Labor Market Runs Hot; UiPath, Marvell React to Earnings - InvestorsObserver

Mon, 28 Nov 2022
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch

Tue, 15 Nov 2022
Fortress Biotech Non-GAAP EPS of -$0.08 misses by $0.01, revenue of $16.5M misses by $5.13 - Seeking Alpha

Tue, 15 Nov 2022
Fortress Biotech: Q3 Earnings Snapshot - Idaho Statesman

Mon, 14 Nov 2022
Twist Bioscience (TWST) Surges 16.1%: Is This an Indication of Further Gains? - Yahoo Eurosport UK

Thu, 10 Nov 2022
Fortress Biotech, Inc. (FBIO) Q3 2022 Earnings Call Transcript - Seeking Alpha

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 108 (M)
Shares Float 72 (M)
% Held by Insiders 26.4 (%)
% Held by Institutions 30.1 (%)
Shares Short 605 (K)
Shares Short P.Month 747 (K)

Stock Financials

EPS -0.87
EPS Est Next Qtl -0.47
EPS Est This Year -1.63
EPS Est Next Year -1.63
Book Value (p.s.) 0.72
Profit Margin (%) -108.9
Operating Margin (%) -240.8
Return on Assets (ttm) -31.7
Return on Equity (ttm) -110
Qtrly Rev. Growth 5.8
Gross Profit (p.s.) -0.8
Sales Per Share 0.76
EBITDA (p.s.) -1.78
Qtrly Earnings Growth 0
Operating Cash Flow -149 (M)
Levered Free Cash Flow -107 (M)

Stock Valuations

PE Ratio -0.76
PEG Ratio -0.1
Price to Book value 0.9
Price to Sales 0.85
Price to Cash Flow -0.48

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.